$54.36
1.41% yesterday
Nasdaq, Sep 19, 10:14 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$54.36
-2.95 5.15% 1M
-16.96 23.78% 6M
-11.37 17.30% YTD
-17.05 23.88% 1Y
-33.34 38.02% 3Y
-22.92 29.66% 5Y
-67.73 55.48% 10Y
+45.61 521.26% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
-0.78 1.41%

Key metrics

Basic
Market capitalization
$10.6b
Enterprise Value
$9.8b
Net debt
positive
Cash
$1.4b
Shares outstanding
192.0m
Valuation (TTM | estimate)
P/E
16.6 | 15.8
P/S
3.5 | 3.3
EV/Sales
3.2 | 3.0
EV/FCF
14.1
P/B
1.8
Financial Health
Equity Ratio
81.0%
Return on Equity
7.5%
ROCE
12.3%
ROIC
11.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.1b | $3.2b
EBITDA
$853.8m | $905.2m
EBIT
$829.4m | $841.9m
Net Income
$657.2m | $670.0m
Free Cash Flow
$691.2m
Growth (TTM | estimate)
Revenue
18.4% | 13.3%
EBITDA
165.4% | 47.6%
EBIT
198.5% | 47.7%
Net Income
156.1% | 57.0%
Free Cash Flow
224.7%
Margin (TTM | estimate)
Gross
79.6%
EBITDA
27.9% | 28.0%
EBIT
27.1%
Net
21.5% | 20.7%
Free Cash Flow
22.6%
More
EPS
$3.3
FCF per Share
$3.6
Short interest
4.0%
Employees
3k
Rev per Employee
$940.0k
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Biomarin Pharmaceutical forecast:

28x Buy
82%
6x Hold
18%

Analyst Opinions

34 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
82%
Hold
18%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,064 3,064
18% 18%
100%
- Direct Costs 626 626
21% 21%
20%
2,437 2,437
18% 18%
80%
- Selling and Administrative Expenses 905 905
5% 5%
30%
- Research and Development Expense 678 678
14% 14%
22%
854 854
165% 165%
28%
- Depreciation and Amortization 24 24
44% 44%
1%
EBIT (Operating Income) EBIT 829 829
199% 199%
27%
Net Profit 657 657
156% 156%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
Seeking Alpha
10 days ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Rese...
Neutral
PRNewsWire
12 days ago
Children who received VOXZOGO showed anatomical improvements in spinal morphology VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset SAN RAFAEL, Calif. , Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from 14 studies were presented at the American Society for Bone and Mineral Research 20...
Neutral
PRNewsWire
14 days ago
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif. , Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALY...
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today